Literature DB >> 29336478

Apelin-13 treatment enhances the stability of atherosclerotic plaques.

Rodrigo A Fraga-Silva1, Hugo Seeman2, Fabrizio Montecucco3,4,5, Analina R da Silva3, Fabienne Burger6, Fabiana P Costa-Fraga1, Léa Anguenot1, François Mach6, Robson A S Dos Santos2, Nikolaos Stergiopulos1, Rafaela F da Silva2.   

Abstract

BACKGROUND: Apelin is an endogenous peptidergic system which modulates cardiovascular function. Recent studies pointed out a fundamental contribution of apelin on atherosclerosis development; however, such reports revealed contradictory data, and to date, it is difficult to accurately define a beneficial or deleterious role. To better understand apelin function on atherosclerosis, we aimed to investigate apelin-13 treatment effects on atherosclerotic plaques composition.
DESIGN: Apolipoprotein E gene-deleted mice were fed on Western-type diet for 11 weeks. Atherosclerotic plaque formation was induced in the carotid artery by a shear stress modifier device, which exposes the same vessel to distinct patterns of shear stress enabling the formation of plaques with different composition. Mice were treated with apelin-13 (2 mg kg-1 day-1 ) or vehicle for the last 3 weeks.
RESULTS: Apelin-13 treatment did not alter the lipid content of low shear stress- and oscillatory shear stress-induced plaques in the carotid. However, apelin-13 greatly ameliorated plaque stability by increasing intraplaque collagen content and reducing MMP-9 expression. Furthermore, apelin-13 decreased the infiltration of inflammatory cells (neutrophil and macrophage) and intraplaque reactive oxygen species content. Interestingly, apelin-13 treatment reduced total cholesterol, LDL levels and free fatty acid serum levels, while HDL, triglycerides serum levels were not significantly changed.
CONCLUSIONS: Apelin-13 treatment for 3 weeks did not alter the lesion size, but it significantly enhanced the stable phenotype of atherosclerotic plaques and improved serum lipid profile. These results indicate that activation of apelin system decreases plaque vulnerability.
© 2018 Stichting European Society for Clinical Investigation Journal Foundation.

Entities:  

Keywords:  APJ receptor; apelin; atherosclerosis; plaque stability; vulnerable plaque

Mesh:

Substances:

Year:  2018        PMID: 29336478     DOI: 10.1111/eci.12891

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  4 in total

Review 1.  Cardioprotective apelin effects and the cardiac-renal axis: review of existing science and potential therapeutic applications of synthetic and native regulated apelin.

Authors:  Carina Ureche; Laura Tapoi; Simona Volovat; Luminita Voroneanu; Mehmet Kanbay; Adrian Covic
Journal:  J Hum Hypertens       Date:  2019-01-18       Impact factor: 3.012

2.  Plasma levels of Elabela are associated with coronary angiographic severity in patients with acute coronary syndrome.

Authors:  Sheng-Li DU; Xin-Chun Yang; Jiu-Chang Zhong; Le-Feng Wang; Yi-Fan Fan
Journal:  J Geriatr Cardiol       Date:  2020-11-28       Impact factor: 3.327

Review 3.  The Role of Apelin-APJ System in Diabetes and Obesity.

Authors:  Cheng Li; Hongna Cheng; Binay Kumar Adhikari; Shudong Wang; Na Yang; Wenyun Liu; Jian Sun; Yonggang Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-09       Impact factor: 5.555

Review 4.  The beneficial roles of apelin-13/APJ system in cerebral ischemia: Pathogenesis and therapeutic strategies.

Authors:  Jiabin Li; Zhang Chen; Jingyu Chen; Yue Yu
Journal:  Front Pharmacol       Date:  2022-08-10       Impact factor: 5.988

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.